Mirum Pharmaceuticals Presents at Evercore Healthcare Conference with $500M-$510M Revenue Guidance and Positive Cash Flow

Mirum Pharmaceuticals, a rare disease company, expects $500mln-$510mln in revenues this year and is cash flow positive. The company has a full pipeline led by volixibat for adult cholestatic diseases and MRM-3379 for Fragile X syndrome, where the first patient was enrolled in a Phase II trial yesterday. Mirum aims to tap into the $1 bln-plus Fragile X market.